Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 10, Issue 3, 2004, Pages 376-380

  Xiao, Wen Hua ^a   Liu, Wei Wen ^b  

^a 304TH HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; NUCLEOTIDE; THIAMINE; TRANSCRIPTION FACTOR RUNX3;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; FEMALE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HEMIZYGOTE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; METHYLATION; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 1142299739     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i3.376     Document Type: Article

References (38)

1. Kloos DU, Choi C, Wingender E. The TGF-beta-Smad network: Introducing bioinformatic tools. Trends Genet 2002; 18: 96-103
2. Moustakas A, Pardali K, Gaal A, Heldin C. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 2002; 82: 85-91
3. Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, Adams SL. Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am 2001; 83A (Pt 1): S15-22
4. Zaidi SK, Sullivan AJ, Van Wijnen AJ, Stein JL, Stein GS, Lian JB. Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci U S A 2002; 99: 8048-8053
5. Li QL, Ito K, Sakaura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-124
6. Korn WM. Moving toward an understanding of the metastatics process in hepatocellular carcinoma. World J Gastroenterol 2001; 7: 777-778
7. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193-199
8. Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995; 21: 760-766
9. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, TakaishiK, Kiso S, Matsuzawa Y. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with other liver diseases. Cancer 1994; 73: 2275-2279
10. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, Shin JW, Lee HC, Lee YS, Suh DJ. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002; 94: 175-180
11. Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sugano Y, Yamashiki N, Nakagawa T, Seki T, Nishizawa M, Fujisawa J, Inoue K. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: Implications for roles of smads in its growth. Hepatology 2000; 32: 218-227
12. Kawate S, Takenoshita S, Ohwada S, Mogi A, Fukusato T, Makita F, Kuwano H, Morishita Y. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol 1999; 14: 127-131
13. Kawate S, Ohwada S, Hamada K, Koyama T, Takenoshita S, Morioshita Y, Hagiwara K. Mutational analysis of the Smad 6 and Smad 7 genes in hepatocellular carcinoma. Int J Mol Med 2001; 8: 49-52
14. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cains P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. Cancer Res 1996;l 56: 2527-2530
15. Simon D, Knowles BB, Weith A. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas. Oncogene 1991; 6: 765-770
16. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res 1994; 54: 4188-4192
17. Fang W, Piao Z, Simon D, Sheu JC, Huang S. Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region. Genes Chromosomes Cancer 2000; 28: 269-275
18. Huang S. The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers. Front Biosci 1999; 4: D528-D532
19. Kuroki T, Fujiwara Y, Tsuchiya E, Nakamori S, Imaoka S, Kanematsu T, Nakamura Y. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: Loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 1995; 13: 163-167
20. Sun M, Eshleman JR, Ferrell LD, Jacobs G, Sudilovsky EC, Tuthill R, Hussein MR, Sudilovsky O. An early lesion in hepatic carcinogenesis: Loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001; 33: 1415-1424
21. Liu LH, Xiao WH, Liu WW. Effect of 5-Aza-2′-deoxycytidine on the p16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2. World J Gastroenterol 2001; 7: 131-135
22. Lehmann U, Hasemeier B, Lilischkis R, Kreipe H. Quantitative analysis of promoter hypermethylation in laser-microdissected archival specimens. Lab Invest 2001; 81: 635-638
23. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: Systematic investigation of critical experimental parameters. Nucleic Acids Res 2001; 29: E65
24. Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D, Lotem J, Ben-Asher E, Lancet D, Levanon D, Groner Y. The RUNX3 gene-sequence, structure and regulated expression. Gene 2001; 279: 221-232
25. Cohen MM Jr. RUNX genes, neoplasia, and cleidocranial dysplasia. Am J Med Genet 2001; 104: 185-188
26. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196
27. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-3229
28. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-167
29. Wajed SA, Laird PW, DeMeester TR. DNA methylation: An alternative pathway to cancer. Ann Surg 2001; 234: 10-20
30. Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, Gennari L, Tommasini M, Malesci A, Coggi G. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 2002; 36: 427-432
31. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999: 59: 793-797
32. Li Q, Ahuja N, Burger PC, Issa JP. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 1999; 18: 3284-3289
33. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J Mol Med 2001; 79: 428-436
34. Jones PA. Cancer. Death and methylation. Nature 2001; 409: 141-144
35. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002; 94: 755-761
36. Zhong S, Tang MW, Yeo W, Liu C, Lo YM, Johnson PJ. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res 2002; 8: 1087-1092
37. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35
38. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, Linehan M, Baylin SB. Regional DNA hypermethylation at D17S5 precedes structural changes in the progression of renal tumour. Cancer Res 1993; 53: 2719-2722